Epidermal Growth Factor Receptor Exon 19 Deletions Predict Complete Regression of Multiple Intracranial Metastases in Two Cases of Non-small Cell Lung Cancer Treated with Erlotinib  by Benedetti, Giovanni et al.
LETTERS TO THE EDITOR
Epidermal Growth
Factor Receptor Exon
19 Deletions Predict
Complete Regression
of Multiple Intracranial
Metastases in Two
Cases of Non-small Cell
Lung Cancer Treated
with Erlotinib
To the Editor:
The incidence of intracranial me-
tastases in non-small cell lung cancer
(NSCLC) is increasing as a result of
both advances in neuroimaging and in-
creased survival, and a synchronous pre-
sentation with the primary lung disease
is not uncommon. Whole-brain radiation
therapy (WBRT) can prolong the me-
dian survival by only 1 to 3 to 6 months,
and chemotherapeutic regimens have re-
sponse rates below 20%, with median
survivals of 4 to 6.5 months.1 Recently,
Caucasian patients treated with Gefitinib
or Erlotinib have experienced unex-
pected activity against brain metastases,
revealing the ability of small-molecule
tyrosine kinase inhibitors (TKIs) to
cross the blood brain barrier. Phase II
trials using Gefitinib or Erlotinib for
NSCLC harboring epidermal growth
factor receptor (EGFR) mutations have
recently shown a higher response rate
for metastases to all sites, included mul-
tiple intracranial lesions.2 The Spanish
Lung Cancer Group monitored a sub-
group of chemotherapy-naive, EGFR-
mutated NSCLC patients with intracra-
nial lesions who were treated with
erlotinib: four complete responses and
three partial responses were reported.3
Fekrazad et al.4 published a case of a
nonsmoking native American woman
who had a complete and continued re-
gression of the brain metastases from a
lung adenocarcinoma using Erlotinib,
whereas WBRT had failed to control the
same lesions. The primary lung tumor
mass was partially controlled. However,
these authors did not analyze EGFR mu-
tations.
Numerous studies have analyzed
the prognostic and predictive signifi-
cance of the mutational spectrum of
EGFR. Murray et al.5 described an ana-
lytical database of 12,244 patients with
3381 somatic EGFR mutations They cat-
alogued mainly the somatic mutational
spectrum of exons 18–21 of EGFR, with
50% of the mutations being exon 19 de-
letions or deletional insertions. A clear
association between EGFR mutations and
a response to TKIs was confirmed, but no
specific behavior regarding intracranial
metastases was identified. Moreover,
there is no specific analysis that corre-
lates treatment with TKIs and the re-
sponse at a particular disease site, al-
though observations of this phenomenon
are accumulating.
Here, we report two cases of
NSCLC in which the EGFR exon 19
deletion predicted complete regression
of multiple intracranial metastases
treated with Erlotinib.
Case 1 was a 44-year-old, non-
smoking man who underwent total body
computed tomography (CT) because he
developed sudden right hemiplegia. A
2.7-cm tumor in the left lung with con-
comitant bilateral parenchymal metasta-
ses and synchronous multiple intracra-
nial metastases (MIMs) ranging in size
from 1 to 3.3 cm were found (Figure
1A). Adenocarcinoma of the lung was
diagnosed after a transbronchial biopsy.
The patient refused WBRT, and the cis-
platin and etoposide chemotherapy was
stopped at the second cycle because of
an anaphylactic reaction. At that time,
both the lung and intracranial lesions
persisted unchanged, as shown by CT. A
new sample of tumor tissue was ob-
tained, and the molecular analysis iden-
tified the L747-P753 deletion of EGFR
exon 19. Erlotinib 150 mg/d was admin-
istered orally with no clinically relevant
side effects, except a mild skin rash.
After 6 months, all of the intracranial
lesions had disappeared, although a fi-
brotic image remained in the left lung on
positron emission tomography-CT (Fig-
ures 1A, B). The patient died 15 months
later from a relapse and disease progres-
sion. No data were available regarding a
possible T790M EGFR gene mutation.
Case 2 was a 48-year-old, Cauca-
sian woman who smoked and presented
with a lung neoplasm, synchronous metas-
tases to the liver, spleen, and bones, and
MIMs. Histologically, a transbronchial
fine-needle aspiration showed large cell
carcinoma of the lung. The patient was
treated with four cycles of cisplatin plus
fotemustine, followed by WBRT. Sta-
ble disease was obtained. However, 3
months later, disease progression was
documented on CT scan, and the levels
of the serological tumor markers CEA
and CA-125 were 115 g/ml and 494
U/ml, respectively. Molecular analysis
of a tumor sample showed an EGFR
deletion in exon 19 (K745_E749del).
Subsequently, the patient was given Er-
lotinib 150 mg/d orally beginning in
February 2007. Four months later, the
MIMs had disappeared completely, and
the lung, bone, liver, and spleen metas-
tases had regressed partially. The CEA
and CA-125 fell to normal levels. The
disease had remained stable at the last
follow-up visit, after 24 months of Erlo-
tinib treatment.
These experiences confirm that in-
tracranial NSCLC metastases can re-
gress completely and for long time after
treatment with Erlotinib in cases in
which standard systemic chemotherapy
and radiation therapy were useless. This
is striking, because until now the central
nervous system has been considered a
sanctuary limiting the activity of all
medical oncology strategies. Moreover,
Erlotinib seems to be site specific for
intracranial metastases harboring EGFR
exon 19 deletions. Perspective studies in
selected patients are needed to confirm
these observations. In addition, it would
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be useful to analyze the penetration of
erlotinib into the central nervous system
and the development of resistance, to
possibly explain differences in re-
sponses and relapses.
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Asymptomatic Air
Embolism After
Computed
Tomography-Guided
Lung Needle Marking
To the Editor:
Computed tomography (CT)-
guided lung needle marking has become a
frequently used method to localize a small
lung nodule before video-assisted thoraco-
scopic surgery (VATS). Although the pro-
cedure is associated with various com-
plications, air embolism is extremely
rare and sometimes fatal. As most of air
embolism is diagnosed by clinical
symptoms, its frequency might be un-
derestimated in patients without car-
diac or cerebral symptoms. Here, we
report a case of asymptomatic air em-
bolism after CT-guided lung needle
marking.
The patient was 65-year-old man
with no symptoms. Chest CT showed a
small nodule in the segment 6 of the right
lower lobe. CT-guided lung needle mark-
ing was performed to identify the tumor
for planned VATS resection. The patient
was placed in a prone position. After the
local anesthesia, a 21-gauge marking nee-
dle (Guiding-Marker System, Hakko, To-
kyo, Japan) was inserted into the right
lower lobe and a hook wire marker was
placed under intermittent CT guidance
(Figure 1). Although the patient did not
complain of any symptoms, postproce-
dural CT showed air in the right inferior
pulmonary vein and left atrium (Figure 2).
Twenty minutes later, the air disappeared
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FIGURE 1. A, Case 1: Computed tomography (CT) images of synchronous multiple intracranial metastases in a non-small cell
lung cancer (NSCLC) patient before erlotinib treatment. B, Case 1: Positron emission tomography-CT showing dimensional
and functional complete remission of multiple intracranial metastases (MIMs) after 8 months of erlotinib treatment.
FIGURE 1. Postprocedural computed
tomography (CT) scan shows the hook
wire marker (small arrow) placed near
the pulmonary nodule (large arrow).
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